– USA, CA – Pfenex Inc. (NYSE: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins, today announced the election of John Taylor to the company’s board of directors following the company’s annual meeting of stockholders.
“John Taylor brings more than 20 years of regulatory experience working with the U.S. Food and Drug Administration (FDA) that will be invaluable to Pfenex’s board of directors and management team as we move forward in the development and commercialization of our biosimilar pipeline,” stated Bertrand C. Liang, chief executive officer of Pfenex. “His track record in supporting global regulatory operations is highly relevant to our ongoing efforts and execution of our business plan.”
Mr. Taylor joins Pfenex’s Board of Directors after a distinguished career with the FDA, including most recently Counselor to the Commissioner, and previously Acting Deputy Principal Commissioner and Deputy Commissioner for Global Regulatory Operations and Policy. His previous experience also includes being Divisional Vice President for Federal Government Affairs at Abbot Laboratories, as well as Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Currently Mr. Taylor is a Principal at Greenleaf Health LLC, a full-service consulting firm that provides strategic guidance to FDA-regulated companies that are developing innovative solutions to pressing public health challenges.
Mr. Taylor has received multiple honors, including the Health and Human Services Secretary’s Award for Distinguished Service (1997, 2000, 2003, 2004, 2005 and 2011) and the FDA Award of Merit (2000, 2003 and 2005). He received his J.D. from the College of William and Mary and is a graduate of Pennsylvania State University with a B.A. in History.
About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
